FDA/CDC

FDA approves afamelanotide for treatment of rare condition with light-induced pain


 

The Food and Drug Administration has approved afamelanotide (Scenesse) to “increase pain-free light exposure” in adults with a history of phototoxic reactions from erythropoietic protoporphyria, a rare condition that causes extremely painful reactions when skin is exposed to light, according to an FDA announcement.

A stamp saying "FDA approved." Olivier Le Moal/Getty Images

This is the first treatment approved to help patients with this condition increase their exposure to light, according to the release.

Afamelanotide, administered in a subcutaneous implant, is a melanocortin-1 receptor (MC1-R) agonist, which “increases the production of eumelanin in the skin independent of exposure to sunlight or artificial light sources,” the release says.

Approval is based on a pair of parallel-group clinical trials that compared the number of hours spent in sunlight in the treatment and placebo groups. The first trial enrolled 93 patients; 48 received afamelanotide. The treated patients spent a median of 61 hours in total over 180 days in direct sunlight between 10 a.m. and 6 p.m. on days with no pain, compared with 41 hours for patients taking placebo.

The second trial assessed the total number of hours over 270 days spent outdoors between 10 a.m. and 3 p.m. on days with no pain for which “most of the day” was spent in direct sunlight. In this study, 38 patients treated with afamelanotide spent a median total of 6 hours, compared with 0.75 hours among the remaining 36 who were taking a placebo.

The most common side effects include implant site reaction, nausea, and oropharyngeal pain. The implant should be administered only by trained professionals. Because afamelanotide may cause skin darkening, it’s recommended that patients should undergo twice-yearly skin examinations. Patients are also encouraged to maintain sun protection measures to help prevent phototoxic reactions.

“Today’s approval is one example of the FDA’s ongoing commitment to encourage industry innovation of therapies to treat rare diseases, and work with drug developers to make promising new therapies available to patients as safely and efficiently as possible,” said Julie Beitz, MD, director of FDA’s Center for Drug Evaluation and Research Office of Drug Evaluation III in the FDA release.

Recommended Reading

2018: A banner year for hematology drug approvals
Journal of Clinical Outcomes Management
FDA approves Zolgensma for infantile-onset SMA treatment
Journal of Clinical Outcomes Management
Pazopanib extended PFS in patients with carcinoid tumors
Journal of Clinical Outcomes Management
Mutant huntingtin and neurofilament light are potential biomarkers in Huntington’s disease
Journal of Clinical Outcomes Management
CDC: Look for early symptoms of acute flaccid myelitis, report suspected cases
Journal of Clinical Outcomes Management
Study refines ALS risk among first-degree relatives of patients with disease
Journal of Clinical Outcomes Management
Hospital slashes S. aureus vancomycin resistance
Journal of Clinical Outcomes Management
‘Pot’ is still hot for Dravet, Lennox-Gastaut
Journal of Clinical Outcomes Management
New genotype of S. pyrogenes found in rise of scarlet fever in U.K.
Journal of Clinical Outcomes Management
C-Path and NORD team up to speed development of treatments for rare disorders
Journal of Clinical Outcomes Management